The advent of point-of-care (POC) diagnostic capabilities has enabled rapid and timely clinical evaluation in the
physician's office, an ambulance, the home, the field, or in the hospital and has the potential to significantly
impact health care delivery. In cardiology, pulmonology/critical care, and hematology, POC testing plays an
especially significant role as the heart and lungs are among the most vital of organs necessitating real time
diagnosis and rapid management during critical illnesses, while pathologic alternations in blood are associated
with critical, systemic illness. One class of novel medical technologies that is showing promise for POC
applications are microsystems-engineered technologies, that is, microchip-enabled devices ranging from
microelectromechanical systems (MEMs)-based sensors, microfluidics, to even smartphone-based systems.
Notable for their small size and power requirements, microchip-based systems provide the portability that is
vital for POC testing. In addition, the capability of microsystems to convert sound and movement into electrical
signals enable these technologies to be ideal devices to sense the dynamics of the lungs and heart and
therefore to diagnose and monitor pulmonary and cardiac disorders. Moreover, microsystems engineering has
brought forth the field of microfluidics, which is steadily finding applications for blood-based diagnostics, and
therefore, hematologic applications. To that end, per the NHLBI's U54 POCTRN guidelines, the overall goal of
the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to assist and enable
inventors from across the country who have developed microsystems-based POC technologies for cardiac,
pulmonary, hematologic and sleep applications that are beyond proof-of-concept to define their specific clinical
needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to
translation and clinical adoption and directly addressing the barriers thereof. The ACME POCT uniquely
leverages Atlanta's nationally top-ranked clinical programs at Emory University's hospitals and Children's
Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well the internationally
acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute for Electronics
and Nanotechnology (IEN), and other one-of-a-kind medical device prototyping, innovation, and testbed
facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and
comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise
in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems
engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and
head of clinical research in Atlanta's NIH-funded CTSA. Importantly, the leadership of the ACME POCT has a
history of collaboration and track record in managing Centers that have fostered medical device development.
Public Health Relevance Statement
The overall goal of the Atlanta Center for Microsystems Engineered POC Technologies (ACME POCT) is to
assist and enable inventors from across the country who have developed microsystems-based POC
technologies for cardiac, pulmonary, hematologic and sleep applications that are beyond proof-of-concept to
define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of
accelerating the path to translation and clinical adoption and directly addressing the barriers thereof. The
ACME POCT uniquely leverages Atlanta's nationally top-ranked clinical programs at Emory University's
hospitals and Children's Healthcare of Atlanta, one of the nation's largest pediatric hospital systems, as well
the internationally acclaimed microsystems engineering expertise at Georgia Tech, which includes the Institute
for Electronics and Nanotechnology, and other one-of-a-kind medical device prototyping, innovation, and
testbed facilities. The ACME POCT PI's uniquely balance the engineering and clinical sides of the Center and
comprise Wilbur Lam, MD, PhD, a clinical hematologist at Emory and Georgia Tech bioengineer with expertise
in POC diagnostic development and commercialization, Oliver Brand, PhD, a renowned microsystems
engineer and head of Georgia Tech's IEN, and Greg Martin, MD, MSc, a clinical pulmonologist at Emory and
head of clinical research in Atlanta's NIH-funded Clinical and Translational Science Awards.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdoptionAmbulancesBedside TestingsBiomedical EngineeringBloodCardiacCardiologyCare Technology PointsCellular PhoneChild health careClinicalClinical ResearchClinical and Translational Science AwardsClinical assessmentsCollaborationsCountryCritical CareCritical IllnessDataDevelopmentDevice or Instrument DevelopmentDevicesDiagnosisDiagnosticDoctor of PhilosophyElectronicsEngineeringEquilibriumFacultyFosteringFundingFutureGeneral PopulationGoalsGuidelinesHeadHealth Services ResearchHeartHeart DiseasesHeart failureHematologistHematologyHome environmentHospitalsInstitutesInternationalLeadershipLungLung diseasesMedical DeviceMedical TechnologyMedicineMicrofluidicsMonitorMovementNanotechnologyNational Heart, Lung, and Blood InstituteOrganPathologicPatientsPediatric HospitalsPhysiciansPhysicians' OfficesPlayProcessPulmonologyRecording of previous eventsRoleSideSignal TransductionSleepSystemTechnologyTestingTimeTraining ActivityTranslationsUnited States National Institutes of HealthUniversity HospitalsValidationbasecommercializationcosthealth care deliveryinnovationmicrochipmicrosensormicrosystemsnoveloperationpoint of carepoint-of-care diagnosticsportabilityprogramsprototyperesearch clinical testingsensorsoundsuccesstechnology developmenttechnology traininguptakeusability
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
30-September-2020
Project End Date
31-May-2023
Budget Start Date
30-September-2020
Budget End Date
31-May-2023
Project Funding Information for 2020
Total Funding
$7,085,000
Direct Costs
$4,840,664
Indirect Costs
$2,244,336
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Biomedical Imaging and Bioengineering
$7,085,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U54EB027690-03S2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U54EB027690-03S2
Patents
No Patents information available for 3U54EB027690-03S2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U54EB027690-03S2
Clinical Studies
No Clinical Studies information available for 3U54EB027690-03S2
News and More
Related News Releases
No news release information available for 3U54EB027690-03S2
History
No Historical information available for 3U54EB027690-03S2
Similar Projects
No Similar Projects information available for 3U54EB027690-03S2